Dr Wing-Hin Lee was awarded a Cancer Institute of New South Wales ECF grant worth $592,183 to develop innovative therapies for lung cancer. Dr Lee's Fellowship will last three years and will investigate the development of a novel drug delivery system for treating lung cancer. To-date no local therapy exists and current approaches result in significant side effects. The proposed technology that he will develop utilises a magnetically trigged nano-carrier system that can be activated during routine imaging in the clinic. Importantly, this technology will only release chemotherapeutics at toxic levels within tumor regions in the lung, minimising side-effects of chemotherapy treatments.
More information about this and other successful funding received by the RespiTech group at the Woolcock Institute of Medical Research can be found here.